Loren M L, Chai H, Leung P, Rohr C, Brenner A M
Ann Allergy. 1980 Aug;45(2):67-71.
In a 72-hour double-blind study 16 moderately to severely asthmatic subjects received either oral prednisone 2 mg/kg/day or placebo in addition to their regular medication as treatment for an acute exacerbation of asthma. The group receiving prednisone demonstrated significant increases in the PEFR and decreased need for beta-2 agonist nebulization or injections the first 12 hours of the study period and these improvements were maintained over the 72 hours. The placebo-treated group showed minimal reduction in nebulization and injection requirements and minimal increase in PEFR. Oral prednisone was found to be effective in controlling acute exacerbations of asthmatic symptoms.
在一项为期72小时的双盲研究中,16名中度至重度哮喘患者除接受常规药物治疗外,还接受口服泼尼松2毫克/千克/天或安慰剂治疗,以治疗哮喘急性加重。接受泼尼松治疗的组在研究期的前12小时内,呼气峰流速(PEFR)显著增加,且对β-2激动剂雾化或注射的需求减少,这些改善在72小时内得以维持。安慰剂治疗组的雾化和注射需求减少最小,PEFR增加也最小。结果发现口服泼尼松对控制哮喘症状的急性加重有效。